James Cancer Hospital / Ohio State University

Columbus, Ohio 43221

0 studies enrolling now · 7 studies all time

What they study most

Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Carcinoma Transitional Cell, Carcinoma in Situ, Carcinoma, Transitional Cell, Disease, Hodgkin, HER2 Positive Breast Cancer, Hodgkin Disease, Hodgkin Lymphoma, NMIBC, Non-muscle Invasive Bladder Cancer, Peripheral T Cell Lymphoma

Studies at this site

• A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) — Stopped early
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer — Completed
• A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) — Completed
• A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer — Completed
• A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma — Completed
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) — Completed
• A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML — Completed